Document is current
Any future updates will be listed below
-
Authors
Boerstler, Tom
Kachkin, Daniil
Gerasimova, Elizaveta
Zagha, Naime
Furlanetto, Federica https://orcid.org/0000-0003-0963-3560
Nayebzade, Negar
Zappia, Luke https://orcid.org/0000-0001-7744-8565
Boisvert, Michelle
Farrell, Michaela
Ploetz, Sonja
Prots, Iryna
Regensburger, Martin https://orcid.org/0000-0002-2172-7386
Günther, Claudia
Winkler, Juergen
Gupta, Pooja https://orcid.org/0009-0009-3328-5157
Theis, Fabian
Karow, Marisa
Falk, Sven
Winner, Beate https://orcid.org/0000-0002-6909-0564
Krach, Florian https://orcid.org/0000-0002-4506-8792
-
Funding
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2024_EKEA.50)
Friedrich Alexander University of Erlangen Nuremberg | Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg (P153, J-122)
Bundesministerium für Bildung und Forschung (01GM1905B, 01GM2209B)
Deutsche Forschungsgemeinschaft (WI 3567/2-1, GRK2162/ 270949263)
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 5 September 2025
First Online: 1 October 2025
Competing interests
: The authors declare no competing interests.
: The human cells used in this study were handled in accordance with the principles outlined in the Declaration of Helsinki. Concerning all UKER lines, informed written consent was obtained from the participating individuals to use donor tissue for research purposes. The generation and use of local human iPSC lines were approved by the Institutional Review Board of the University Hospital of Erlangen (Nr. 4120 and 259_17B: Generation of human neuronal models for neurodegenerative diseases). Concerning iPSC lines Kucg2 and Sojd3 (HipSci feeder-free panel (ECACC 77659901)), the MTA was obtained from the Wellcome Trust Sanger Institute for research purposes. The remaining iPSC lines (TMOi001A, KOLF2.1, CVB) are commercially available. The use of human embryonic stem cells for this project was approved by the Central Ethics Committee for Stem Cell Research (121. Approval according to the German Stem Cell Act to Beate Winner).
